Conventional drug delivery systems face significant limitations including poor bioavailability, nonspecific distribution, systemic toxicity, and inadequate patient compliance, which collectively compromise therapeutic efficacy and safety. Novel drug delivery systems represent a paradigm shift in pharmaceutical sciences, offering sophisticated platforms that overcome these challenges through precise control of drug release kinetics, spatial targeting, and temporal administration. This article reviews state-of-the-art delivery technologies including nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers; hydrogel matrices; microneedle arrays; biodegradable implants; and intelligent stimuli-responsive systems that respond to physiological triggers. These platforms employ diverse release mechanisms including diffusion-controlled, erosion-mediated, osmotic pressure-driven, and externally triggered modalities, combined with passive and active targeting strategies that enhance drug accumulation at disease sites while minimizing off-target effects. Clinical applications span oncology, infectious diseases, central nervous system disorders, and chronic disease management, demonstrating substantial improvements in therapeutic efficacy, reduction of adverse effects, and enhanced patient adherence. Despite remarkable progress, challenges remain in manufacturing scalability, batch-to-batch reproducibility, long-term safety assessment, and regulatory harmonization. Future directions emphasize integration with personalized medicine approaches, incorporation of real-time biosensing for closed-loop delivery, and convergence with digital health technologies to enable truly precision therapeutics that optimize treatment outcomes for individual patients.